• June 16, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. FOR IMMEDIATE RELEASE June 16, 2017 Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. ofmore...
  • June 1, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the William Blair Growth Stock Conference on Tuesday, June 13, 2017, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 3:10 p.m. ET (2:10 p.m. CT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.more...
  • May 25, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2017 Dental and Veterinary Conference on Wednesday, May 31, 2017, in New York, N.Y. Kristin Peck, Executive Vice President and President, U.S. Operations, will represent the company and respond to questions from analysts. She is scheduled to present at 3:00 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation bymore...
  • May 11, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a third quarter 2017 dividend payable to holders of the company’s common stock of $0.105 per share. The dividend is to be paid on Friday, Sept. 1, 2017, to holders of record on Thursday, June 15, 2017. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years ofmore...
  • May 11, 2017
    SHORT HILLS, N.J.--(BUSINESS WIRE)--Speaking to shareholders at the Zoetis Inc. (NYSE:ZTS) annual meeting today in Short Hills, N.J., Chief Executive Officer Juan Ramón Alaix discussed the company’s 2016 performance and strategies for continued growth as the leader in the global animal health industry. “In 2016, we delivered our fourth consecutive year of operational revenue growth and improved profitability since becoming an independent public company,” said Alaixmore...
  • May 4, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2017 and reaffirmed its guidance for full year 2017. The company reported revenue of $1.2 billion for the first quarter of 2017, an increase of 6% compared with the first quarter of 2016. Net income for the first quarter of 2017 was $238 million, or $0.48 per diluted share, an increase of 17% on a reported basis. Adjusted net income1 formore...
  • May 2, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 17, 2017, in Las Vegas, Nev. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 4:00 p.m. ET (1:00 p.m. PT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visitingmore...
  • April 26, 2017
    ZAVENTEM, Belgium--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab), the first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use. Cytopoint is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing 3 kilograms or more. Cytopoint targets andmore...
  • April 13, 2017
    PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) and Nexvet Biopharma plc (Nasdaq:NVET) today announced an agreement in which Zoetis, through a wholly owned subsidiary (“Zoetis Bidco”), will purchase Nexvet, an innovator in monoclonal antibody therapies for companion animals, for a purchase price of US$6.72 per share, representing an aggregate equity valuation of approximately US$85 million. The acquisition will strengthen Zoetis’ pipeline of solutions for chronicmore...
  • April 13, 2017
    PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--COMPANY NAME: ZOETIS INC. HEADLINE: ZOETIS TO ACQUIRE NEXVET FOR US$85 MILLION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY RESTRICTED JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 13 April 2017 ZOETIS TO ACQUIRE NEXVET FOR US$6.72 IN CASH PERmore...